Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.
Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe latest update on the study of lenvatinib and pembrolizumab for advanced melanoma includes detailed definitions and methodologies for evaluating objective response rate, progression-free survival, and duration of response, along with the reporting of adverse events, following the recent posting of results on October 9, 2024.SummaryDifference30%
- Check9 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check16 days agoChange DetectedThe website has been updated to version v2.11.0, with new results submitted, while the previous version v2.10.5 has been removed along with a notice about delays in study record information.SummaryDifference0.9%
- Check23 days agoChange DetectedClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.SummaryDifference0.8%
- Check38 days agoChange DetectedThe website has been updated from version 2.10.2 to 2.10.3.SummaryDifference0.1%
- Check59 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.